Related Experiment Videos
Acute myeloid leukemia in elderly adults
J Tucker1, A E Thomas, W M Gregory
1ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, U.K.
Hematological Oncology
|January 1, 1990
Summary
Intensive chemotherapy for acute myeloid leukemia (AML) in adults over 60 had a high early death rate and resistance. Achieving complete remission (CR) improved survival, suggesting a need for better-tolerated curative treatments.
Area of Science:
- Hematology
- Oncology
- Geriatric Medicine
Background:
- Acute myeloid leukemia (AML) presents unique challenges in elderly adults.
- Treatment decisions for AML in older patients often balance curative intent with potential toxicity.
Purpose of the Study:
- To evaluate the outcomes of intensive chemotherapy for acute myeloid leukemia (AML) in previously untreated adults over 60 years.
- To identify factors predicting complete remission (CR) and survival in this patient group.
Main Methods:
- Retrospective analysis of 115 adult patients over 60 with AML treated between 1978 and 1986.
- Comparison of outcomes between patients receiving intensive chemotherapy (n=88) and those receiving only palliative care (n=27).
Main Results:
- The intensive chemotherapy group experienced a 48% early death rate and 24% resistant disease.
- Complete remission (CR) was achieved in 28% of patients receiving intensive chemotherapy.
- Lower presentation blast counts (<50 x 10(9)/l) predicted both CR achievement and superior survival.
Conclusions:
- Intensive chemotherapy for AML in elderly adults is associated with significant difficulties, including high toxicity and early mortality.
- Despite challenges, achieving CR offers a survival benefit, underscoring the need for developing more tolerable curative regimens for older AML patients.